The BaseLaunch Accelerator, managed and operated by BaselArea.swiss, started on 14 September 2018 with ten projects entering Phase I. Over the next few months, the…
Giacomo di Nepi has a successful history: A high level executive in big corporations, he transitioned towards biotech, currently as CEO of Polyphor, which, in…
Danish company Novo Holdings is investing 6.8 million Swiss francs in the biopharmaceutical Polyphor from the canton of Basel-Landschaft. As a result, it hopes to…
Switzerland’s first electronic health record has been opened in Basel. The University Hospital Basel will soon be offering the service to patients at its clinics.
Terpenes are a class of chemical compounds found in nature that also include clinical substances. Lab synthesis has always been very difficult, but Basel scientists…
An article by Joanna Glasner, Contributor at Techcrunch Startup exit tallies commonly underestimate biotech returns. Unlike most tech deals, the biggest profits in bio often…
Lonza, a pharmaceutical company from Basel, has published pleasing half-year results, with positive momentum driven by its new Consumer Health division. Lonza has reported 8.2 per…
The competition for financing is intense. How and which projects do you choose to back? Julian Bertschinger: At Johnson & Johnson we collaborate with and…